Destaques

Análise de eventos tromboembólicos e trombocitopênicos após vacinação contra COVID-19 com vacinas da AstraZeneca, da Pfizer e da Moderna em 3 países nórdicos.

19 Jun, 2022 | 15:40h

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries – JAMA Network Open

---

Estudo randomizado fase 2 | Segurança e imunogenicidade da vacina da AstraZeneca em crianças de 6-17 anos de idade.

19 Jun, 2022 | 15:37h

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial – The Lancet

Comentário convidado: Increasing children’s global access to COVID-19 vaccines – The Lancet

---

Diretriz | Tratamento da hiperglicemia em pacientes adultos internados.

19 Jun, 2022 | 14:44h

Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline – The Journal of Clinical Endocrinology & Metabolism

Ver também: A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures – The Journal of Clinical Endocrinology & Metabolism

Comentário: Endocrine Society Issues New Guidelines for Hospitalized Patients With Diabetes – Clinical Advisor

Conteúdos relacionados:

Podcast: #330 Inpatient Diabetes with Dr. Dave Lieb – The Curbsiders

Revisão: Managing hyperglycaemia in inpatients – Clinical Medicine Journal

---

Diretriz | Distúrbios funcionais intestinais com diarreia.

19 Jun, 2022 | 14:43h

Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility – UEG Journal

---

Revisão do estado da arte | Revascularização na doença arterial coronariana estável.

19 Jun, 2022 | 14:39h

Revascularization in stable coronary artery disease – The BMJ

---

Revisão sistemática | Inibidores da Janus quinase para o tratamento de COVID-19.

19 Jun, 2022 | 14:38h

Janus kinase inhibitors for the treatment of COVID‐19 – Cochrane Library

Resumo: Are systemic Janus kinase inhibitors an effective treatment for people with COVID-19? – Cochrane Library

---

[Preprint] Estudo randomizado | Ivermectina não beneficia pacientes com COVID-19 leve a moderada no ambiente ambulatorial.

19 Jun, 2022 | 14:36h

Ivermectin for Treatment of Mild-to-Moderate COVID-19 in the Outpatient Setting: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial – medRxiv

Comentário: Study finds no benefit to taking ivermectin for COVID-19 symptoms – Duke University

---

Em um estudo de doadores de sangue nos EUA, a combinação de soroprevalência do SARS-CoV-2 oriunda de infecção ou de vacinação atingiu 94,7%.

19 Jun, 2022 | 14:35h

Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021 – JAMA

 

Comentário no Twitter

In this study of US blood donations, the combined seroprevalence from #SARSCoV2 infection or vaccination reached 94.7% by December 2021. https://t.co/OiHICuWDo4

— JAMA (@JAMA_current) June 13, 2022

 

---

Segurança comparativa das vacinas BNT162b2 e mRNA-1273 em uma coorte nacional de veteranos nos EUA.

19 Jun, 2022 | 14:27h

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans – JAMA Internal Medicine

Comentário: Few differences in safety profiles of Moderna, Pfizer COVID-19 vaccines – Harvard T.H. Chan School of Public Health

 

Comentário no Twitter

1/
TODAY: We compared the safety of #COVID19 mRNA vaccines in the largest healthcare system in the US.

TAKE-HOME MESSAGE: Both Moderna and Pfizer vaccines are quite safe. If interested in vaccination, you can confidently use whichever one is available.https://t.co/fFIlXwH5Qv

— Miguel Hernán (@_MiguelHernan) June 13, 2022

 

---

Breve resumo dos principais fatos atuais e recomendações | Linfadenopatia regional após vacinação contra COVID-19 em pacientes com ou sem suspeita de câncer de mama.

19 Jun, 2022 | 14:21h

Regional Lymphadenopathy Following COVID-19 Vaccination in Patients with or Suspicious of Breast Cancer: A Quick Summary of Current Key Facts and Recommendations – Korean Journal of Radiology

Conteúdos relacionados:

2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients

Axillary lymphadenopathy at the time of COVID-19 vaccination: ten recommendations from the European Society of Breast Imaging (EUSOBI) – Insights into Imaging

Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance – The BMJ

Frequency and outcomes of MRI-detected axillary adenopathy following COVID-19 vaccination – European Radiology

Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care – European Journal of Cancer

---